Ph3 GDC-9545 ER+ HER2- BC (lidERA)
A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784) Read Moreabout Ph3 GDC-9545 ER+ HER2- BC (lidERA)
Phase: III
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). Read Moreabout Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Ph3 LY3484356 ER+ HER2- BC
EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC) Read Moreabout Ph3 LY3484356 ER+ HER2- BC
Phase: III
Ph3 Imlun vs Endo ER+ HER2- BC
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC
Phase: III
Ph3 Selin P53 Endo Carcinoma
A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma
Phase: III
Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556) Read Moreabout Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
Phase: III
INCMGA00012 Endo Cancer
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer
Phase: II
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Ph3 EpiOvarian FallTube PriPeritoneal
(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal
Phase: III
Ph1b TRK-950 Ovarian Peri & Fallopian
A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian
Phase: I
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
PH3 Pac-Carbo-Oreg EO FT or PC
A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC
Phase: III
Ph3 Upif Rilso Ovarian Cancer
A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049) Read Moreabout Ph3 Upif Rilso Ovarian Cancer
Phase: III
Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556) Read Moreabout Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
Phase: III
Ph2 AKT Pac vs Ova fall and Peri
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri
Phase: II
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
Phase: III
Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A)
STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A) Read Moreabout Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A)
Phase: I
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
(FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
Phase: III
STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202) Read Moreabout STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC
Phase: II
STAR Ph3 Ami Laz EGFR-mut NSCLC
A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002) Read Moreabout STAR Ph3 Ami Laz EGFR-mut NSCLC
Phase: III
STAR PH3 EGFRm stage2/3b NSCLC
A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC
Phase: III
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC
Phase: III
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Ph II/III Raptor trial
Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007) Read Moreabout Ph II/III Raptor trial
Phase: II/III
PH2 Brentux+CHP In Tx Naive PTCL
A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL
Phase: II
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020) Read Moreabout Ph3 LOXO-305 vs. InvChoice in CLL/SLL
Phase: III
PH3 R-CHOP +/- Acalab Tx Naive DLBCL
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 70 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001) Read Moreabout PH3 R-CHOP +/- Acalab Tx Naive DLBCL
Phase: III
Ph3 EpiOvarian FallTube PriPeritoneal
(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal
Phase: III
Ph1/2 ZN-c3 + Nirap PROC
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer (ZN-c3-006) Read Moreabout Ph1/2 ZN-c3 + Nirap PROC
Phase: I/II
Ph1b TRK-950 Ovarian Peri & Fallopian
A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian
Phase: I
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
PH3 Pac-Carbo-Oreg EO FT or PC
A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC
Phase: III
Ph3 Upif Rilso Ovarian Cancer
A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049) Read Moreabout Ph3 Upif Rilso Ovarian Cancer
Phase: III
Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556) Read Moreabout Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
Phase: III
Ph2 AKT Pac vs Ova fall and Peri
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri
Phase: II
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
Phase: III
Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A)
STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A) Read Moreabout Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A)
Phase: I
Ph3 EpiOvarian FallTube PriPeritoneal
(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal
Phase: III
Ph1b TRK-950 Ovarian Peri & Fallopian
A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian
Phase: I
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
PH3 Pac-Carbo-Oreg EO FT or PC
A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC
Phase: III
Ph3 Upif Rilso Ovarian Cancer
A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049) Read Moreabout Ph3 Upif Rilso Ovarian Cancer
Phase: III
Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556) Read Moreabout Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
Phase: III
Ph2 AKT Pac vs Ova fall and Peri
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri
Phase: II
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
Phase: III
Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A)
STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A) Read Moreabout Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A)
Phase: I
STAR PH3 Nirap Abira HRR mCSPC
A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002) Read Moreabout STAR PH3 Nirap Abira HRR mCSPC
Phase: III
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001 Read Moreabout STAR PH3 Abi+/-Capi mHSPC CAPItello-281
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
Phase: II
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I